Skip to main content
3SBio Inc. logo

3SBio Inc. — Investor Relations & Filings

Ticker · 1530 ISIN · KYG8875G1029 LEI · 529900P0TQC1E9Y7FN31 HKEX Manufacturing
Open in API
Filings indexed 1,491 across all filing types
Latest filing 2019-08-08 Share Issue/Capital Cha…
Country KY Cayman Islands
Listing HKEX 1530

About 3SBio Inc.

http://www.3sbio.com

3SBio Inc. is a biopharmaceutical enterprise specializing in the integrated research, development, production, and commercialization of innovative biopharmaceutical products. The company operates as a biotechnology firm, focusing on the discovery, development, manufacture, and marketing of biologics, with a particular emphasis on mammalian cell-based biopharmaceuticals. 3SBio addresses critical medical needs by providing an extensive range of products and services to markets both domestically and internationally.

Recent filings

Filing Released Lang Actions
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 August 2018
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities (Revised)' and is addressed to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, including ordinary shares, preference shares, share options, warrants, convertibles, and other share-related instruments for the month ended 31/08/2018. The content focuses on share capital changes, share options, warrants, and convertible bonds, with no financial performance data, earnings, or management commentary. It is a regulatory filing reporting share capital movements rather than a financial report or announcement of voting results. Therefore, it fits best under the category of Share Issue/Capital Change (SHA). The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement of a report.
2019-08-08 English
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 July 2018
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' and details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related activities for the month ended 31/07/2018. It is addressed to the Hong Kong Exchanges and Clearing Limited, indicating it is a regulatory filing related to share capital movements. The content focuses on share capital changes, share options, warrants, and convertible bonds, without any financial performance data, earnings, management discussion, or meeting materials. It is not an announcement of a report but a detailed monthly return on share capital movements. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes.
2019-08-08 English
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 June 2018
Capital/Financing Update Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities (Revised)' and is addressed to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized share capital, issued share capital, share options, warrants, convertibles, and other share-related transactions for the month ended 30/06/2018. The content focuses on share capital changes, share options, warrants, and convertible bonds, which are typical elements of capital structure updates. There is no indication of financial performance data, earnings, management discussion, or audit information. The document is not a report publication announcement but a detailed monthly return on share capital movements. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2019-08-08 English
NOTICE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a short announcement from the board of directors of 3SBio Inc. stating the date of a board meeting to approve and publish the unaudited interim results for the six months ended 30 June 2019. It does not contain the actual financial results or detailed financial data, but merely notifies the market of the upcoming board meeting and the intended approval and publication of the interim results. The document length is only 1305 characters, which is very short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement about a report, not the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for such announcements that do not fit other specific categories.
2019-08-08 English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 July 2019
Capital/Financing Update Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/07/2019, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorised share capital, issued share capital, share options, warrants, convertibles, and other share-related transactions. The content focuses on changes in the company's capital structure and share issuance activities during the month. There are no financial statements, earnings data, management discussion, or audit information. The document is a regulatory filing reporting capital changes and share movements, typical of a capital/financing update. It is not an announcement of a report, nor a full financial report or earnings release. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) supports it being a substantive report rather than a brief announcement.
2019-08-06 English
VOLUNTARY ANNOUNCEMENT - CLINICAL TRIAL APPROVAL OF RECOMBINANT HUMANIZED ANTI-INTERLEUKIN-17A MONOCLONAL ANTIBODY OBTAINED FROM THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by 3SBio Inc. regarding the approval of a clinical trial application for a recombinant humanized anti-interleukin-17A monoclonal antibody by the National Medical Products Administration. It provides information about the product, its medical context, and a statement from the chairman. The document is relatively short (4612 characters) and does not contain financial data, financial statements, or detailed report content. It is an announcement of a business development event rather than a financial report or regulatory filing. There is no indication that this is an Annual Report, Interim Report, Earnings Release, or any other formal financial or regulatory filing. It is also not a report publication announcement since it does not mention any report being attached or published. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2019-08-01 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.